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A Cardiac myxoma is a benign gelatinous growth 
composed of primitive connective tissue cells and 
stroma resembling mesenchyme that is usually 
pedunculated and usually arises from the interatrial 
septum, near the fossa ovalis. The majority (75%) arise 
within the left atrium. They may be distinguished from 
thrombi by their endothelial lining and the presence of 
endothelium-lined crevices and clefts on their surface. 
Classification 
Note 
Cardiac myxomas are typically described by the 
chamber in which they are located (e.g. atrial 
myxoma), the side of the heart affected (right vs. left) 
and their position within a given chamber (posterior 
wall, anterior wall, interatrial septum or atrial 
appendage). Thus a cardiac myxoma may be described 
as a left atrial myxoma of the anterior wall (for 
example). 
Clinics and pathology 
Phenotype / cell stem origin 
Cardiac Myxomas exhibit a heterogenous phenotype, 
with adult cells expressing protein antigens specific to 
various cell lineages, often within the same tumour, 
including epithelial, endothelial, myogenic, 
myofibroblast, neural and neuro-endocrine antigens. 
Whilst ultrastructural analysis suggests an endothe-lial 
derivation, there is considerable dispute as to  
the outcomes of immunohistochemical investiga-tion. It 
is believed that cardiac myxomas are derived from a 
pluripotent stem cell or a sub-endothelial vasiform 
reserve cell. The ultrastruc-tural findings suggesting an 
endothelial origin are supported by recent 
investigations demonstrating the presence of 
Nkx2.5/Csx cardiac homeobox gene transcript 
expression, and the presence of eHAND transcription 
factors within tumour cells, suggesting a primitive 
cardiomyocyte phenotype. This argu-ment, however, is 
weakened by the recent discovery of the presence of 
Nkx2.5/Csx activation in skeletal myoblasts, and the
proliferative effect of Nkx2.5/ Csx on neuronal 
differentiation in vitro. This evidence is supported by 
the expression of alpha-smooth muscle actin and alpha-
cardiac actin in myxomas; indeed, complex myxoma 
structures (e.g. capillary-like structures) appear to 
express CD34 on their deeper aspects, with greater 
alpha-smooth muscle actin expressed on the superficial 
aspects, suggesting a vessel-like differentiation. 
Cardiac Myxomas also show variable response to other 
antisera, including factor VIII-related antigen, Ulex 
europaeus agglutinin, vimentin, desmin, myoglobin, S-
100 and cytokeratin. Given the variable response to 
such a broad range of antisera, combined with 
ultrastructural appearance that commonly suggests an 
endothelial derivation, but has also been recognised to 
suggest neural or neuro-endocrine origins, current 
thought suggests that it is most likely that cardiac 
myxomas are derived from a pluripotent mesenchymal 
stem cell or sub-endothelial vasiform reserve cell 
located around the fossa ovalis and surrounding 
endocardium. This cell type appears to most commonly 
following an endothelial lineage, but is capable of 
differentiation into other cellular phenotypes. The 
precise nature of this progenitor cell is not known. 
It is important to note that phenotypic expression s 
variable in these tumours and does not necessarily 
reflect the tumour origin. It is also important to n te the 
difference between cardiac myxomas and Prichard's 
structures, which appear to be minute, age-related, 
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endothelial deformities, and not benign neoplastic 
growths. 
Etiology 
Most cardiac myxomas are sporadic and arise as 
isolated masses in the left atrium. The precise aetiology 
of cardiac myxomas has proved difficult to delineate, 
and appears to be related to autosomal dominant gene
mutations as described below. 
Epidemiology 
Cardiac myxomas can occur across all age groups, 
however, they occur with the greatest frequency 
amongst between the third and sixth decades of life. 
The tumours occur as one of three epidemiological 
groups of tumour; sporadic cardiac myxomas (by far 
the most common, with a mean age 56 years old), 
familial cardiac myxomas and complex cardiac 
myxomas. 
Familial cardiac myxomas usually suggest an 
autosomal dominant inheritence pattern and exhibit a 
variable phenotype. Patients with familial cardiac 
myxomas are generally younger at first diagnosis than 
those patients presenting with sporadic cardiac 
myxomas. 
Complex cardiac myxomas are a classification of 
familial tumours, and occur as a syndromic 
presentation, requiring the presence of a cardiac 
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Haemodynamic derangement is the most common 
clinical manifestation of cardiac myxomas, and is due 
to the ability of the tumour to obstruct pulmonary or 
venous drainage, or impair flow across the atrio-
ventricular valves causing a filling defect. Obstruc ion 
of the AV valve orifice occurs more commonly with 
larger, pedunculated tumours, capable of occluding the 
valve orifice. 
The obstruction due to cardiac myxoma is 
characteristically progressive and may be associated, s 
the tumour grows, with intermittent syncope, 
apparently related to postural change, or sudden cardiac 
death. These manifestations occur in approximately 
25% of patients with left atrial myxomas, 33% of 
patients with right atrial myxomas and 50% of patients 
with left ventricular myxomas. 
Impairment of valve closure is either due to direct 
obstruction of the valve orifice by the tumour or 
damage to the leaflets or chordal apparatus by a 
pedunculated tumour capable of 'swinging' into the 
ventricle during atrial systole (the "wrecking ball" 
effect). Damage to the leaflets and chordal appara-tus 
leads to regurgitant flow across the valve structure; 
whilst this occurs in isolation in a minority of patients, 
it is important to note that obstruction of the valve 
orifice is the predominant abnormality. 
Embolism 
Embolism is a major feature of cardiac myxomas, with 
systemic embolism occurring in 30-45% of patients 
with a left atrial tumour. Consequently, the differential 
diagnosis in cases of peripheral embolism must include 
cardiac myxoma. 
Emboli are typically derived from tumour fragments, 
detachment of the tumour as a whole, overlying 
thrombi or foci of infection, and have been reported in 
every organ system. Emboli may pass to the coronary 
arteries resulting in occlusion and angina or infarction. 
Cerebral emboli characteristically lead to persistent 
neurological dysfunction, and are reasonably common, 
with 50% of emboli involving intra- or extra-cranial 
arteries to the central nervous system. 
Large emboli have also been reported as having 
blocked the abdominal aortic bifurcation. 
Left ventricular myxomas have a higher rate of 
embolism (64%) than those in other locations, and te  
to embolise to the brain more frequently than to other 
sites in the systemic circulation. 
Right sided myxomas embolise in approximately 10% 
of cases, and have the potential to cause fatal 
pulmonary artery obstruction, although this is rare in 
comparison to rates of true thromboembolism to the 
pulmonary arteries in patients with systemic tumour 
emboli from a left atrial myxoma. It has also been 
theorised that multiple emboli from a right-sided 
myxoma may lead to the development of pulmonary 
hypertension. 
Constitutional manifestations 
Constitutional manifestations occur in approxi-mately 




- An erythematous rash 
- Arthralgia 
- Myalgia 
- Weight loss, and 
- Raynaud's phenomenon. 
Polycythaemia with or without associated arterial 
hypoxia and clubbing associated with right-to-left 
shunts via an atrial septal defect or patent foramen 
ovale are unusual, but important manifestations of 
cardiac myxoma. 
Haemolytic anaemia occurs in approximately 33% of 
cases is due, as is the occasional associated 
thrombocytopaenia, to mechanical destruction of the 
formed elements of the blood by abnormal flow across 
the tumour. Haemolytic anaemia in cardiac myxoma is 
particularly associated with calcified tumours. 
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All of the constitutional manifestations of cardiac 
myxoma are reversible following removal of the 
tumour. 
Symptoms 
• Left Atrial Myxomas 
Symptoms associated with left atrial myxomas are 
primarily due to the haemodynamic derangement 
caused by the tumour, and very similar in presenta-tion 
to that of mitral stenosis. Dyspnoea and haemoptysis 
predominate in the symptomology and are frequently 
associated with syncope. The symptoms of left atrial 
myxoma may rapidly become severe and intractable, 
and are associated with signs of congestive heart 
failure. 
• Right Atrial Myxomas 
Right-sided tumours may present with episodes of 
syncope and right heart failure, and may progress 
rapidly despite medical treatment. Common symptoms 
associated with the failing right heart are prominent 
jugular a waves, increases in venous pressure, 
abdominal protuberance due to ascites and 
hepatomegaly, and peripheral oedema. The absence of 
orthopnoea and paroxysmal nocturnal dyspnoea in 
these patients is noteworthy. 
Patients may also present with neurological symptoms, 
Raynaud's phenomenon, angina or dyspnoea secondary 
to embolisation from the tumour. Similarly, 
constitutional manifestations may be subtle or absent if 
the tumour is small, yet in rare cases may be the only 
evidence of pathology. 
Signs 
• Left Atrial Myxomas 
Left atrial myxomas may be associated with a loud S1 
heart sound produced by prolonged vibrations 
occurring after mitral valve closure as the tumour 
momentarily comes to rest in the left atrium. Such 
mobile tumours, moving between the left ventricle and 
the left atrium during systole, produce a characteristic 
notch on the ascending limb of the left ventricular 
pressure wave due to the sudden increase in left atrial
volume as the tumour enters the cavity. Consequently, 
the loud S1 sound may also be preceded by an ejection 
sound due to forceful of the tumour from the left 
ventricle to the left atrium. In cases where the tumo r 
remains in the atrium throughout the cardiac cycle, a 
diastolic murmur and pressure tracings practically 
indistinguishable from those of mitral stenosis will 
likely be present. 
The S2 sounds is usually of low intensity and split, and 
an S3 sound is present as an opening snap or 
ventricular gallop. 
• Right Atrial Myxomas 
Right atrial myxomas are associated with a loud, early 
systolic, widely split S1 due to expression of the 
tumour from the right ventricle. A pulmonary ejection 
murmur with a delayed and accentuated pulmonic 
second sound may be heard. There may also be an 
early, late or prolonged diastolic murmur heard. 
• Ventricular Myxomas 
Due to their rarity, the auscultatory findings in 
ventricular myxomas are not fully known, although 
may be similar to those of aortic or pulmonary stenosis. 
Laboratory studies 
Laboratory studies in cardiac myxoma patients tend to 
show elevated total globulin levels with pronounced 
alpha2, beta, and gamma-globulins, localised to the 
IgM and IgA fractions. These are associated with 
elevated erythrocyte sedimentation rate and C-reactive 
protein levels. 
Full blood examination may reveal anaemia. Up to 
33% of cardiac myxoma patients will suffer haemolytic 
anaemia due to the mechanical effects of the tumour on 
the formed elements of the blood. 
Electrocardiography 
ECG findings are non-specific in cardiac myxoma, and
tend to reflect the haemodynamic derangement 
secondary to the tumour, frequently indicating atrial 
enlargement or ventricular hypertrophy. It is not 
unusual for the patients to be in normal sinus rhythm, 
and in contrast to mitral valve disease, findings of atrial 
fibrillation are uncommon. Long-term monitoring may 
reveal supraventricular arrhythmias associated with 
atrial tumours and ventricular arrhythmias associated 
with ventricular tumours. 
Chest Radiography 
Radiographic findings are non-specific in cases of 
cardiac myxoma, generally showing signs of 
pulmonary hypertension and congestion, with possible 
cardiomegaly. 
Echocardiography 
Two-dimensional echocardiography is the investi-
gational modality of choice in case of cardiac myxoma, 
allowing the physician to identify the location, size, 
shape, attachment, and mobility of the tumour, down to 
diameters of approximately 1-3mm. Transthoracic 
echocardiography may be supplemented by 
transoesophageal echocardio-graphy, thus allowing an 
unimpeded view of the atria, atrial septum and regions 
of the ventricles. It is also possible for 
echocardiography to detect cysts, calcifications, 
necrotic foci and haemorrhage within the tumour. 
CT, MRI and Angiography 
CT and MRI imaging modalities are useful in the 
identification of tumours between 0.5-1cm in diameter, 
and have the advantage of allowing multiple thoracic 
slices to be produced without superimposition of the
tissues. Similarly, they allow differentiation of di ferent 
tissue types and may guide the surgeon as to the likely 
gross morphology of the tumour. 
Whilst gated radionuclide cardiac blood-pooling scans 
can depict a myxoma as an intracavitary filling defect, 
general angiography has declined in usefulness with
regards to the diagnosis of myxo-mas, and catherisation 
of the suspected ventricle is contraindicated due to the 
risk of tissue emboli-sation. Angiographic imaging of 
the coronary arteries however, is useful in patients wi h  
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cardiac myxomas (an is indicated in such patients over
the age of 40 years old), given the possibility for
occlusion from tumour emboli. Coronary angio-graphy 
can also establish whether or not tumour vessels are 
supplied from branches of the left or right coronary 
arteries. 
Cytology 
Cardiac myxomas characteristically show a pattern of 
lipid cells embedded in a glycosaminoglycan-rich 
myoxoid stroma. Tumour cells are polygonal and may 
or may not be multinucleated. They possess 
eosinophilic cytoplasm and their nuclei typically 
exhibit an open chromatin pattern. Small areas of 
cellular atypia may be present, but mitoses are absnt. 
The cells may be spread throughout the stroma, or form
clusters around vascular structures, occasionally 
clustering to form capillary-like structures 
communicating with the surface of the tumour. 
10-20% of cardiac myxomas exhibit calcification and 
occasional foci of metaplastic bone, and it is not 
uncommon to find areas of haemorrhage and 
lymphocyte and macrophage infiltration within the 
stroma. 
The surface of the tumour is composed of polygonal 
cells with partial coverings of overlying endothelium. 
The base of the tumour contains many large blood 
vessels originating from the sub-endocardium. 
Pathology 
Cardiac myxomas usually appear as grossly round or 
oval structures with polypoid features, although they 
may occasionally be gelatinous, and many are prone t  
spontaneous fragmentation. 
The tumours appear white, grey-white, or 
yellow/brown, and the surface is often covered by 
thrombi. Tumours can range in size from 1-15cm in 
diameter, although most measure approximately 5-6cm 
across. 
The mobility of tumours within the heart varies 
according to the amount of collagen they contain, the 
degree of attachment to the ventricular wall and the 
length of the stalk attaching them to the heart. 
The precise rate of growth of cardiac myxomas is 
unknown, although it is believed to be reasonably fast. 
Whilst essentially non-malignant, there are reported 
cases of myxoma growth at extra-cardiac sites 
following embolisation. 
Treatment 
Indication For Operation 
Operation for resection of a cardiac myxoma is 
indicated whenever a myxoma is diagnosed. Such 
operations are generally considered urgent proce-dur s, 
especially if there is a history of embolism or syncope, 
as 8-10% of patients awaiting operation die of an 
embolic complication. 
Technique Of Operation 
Surgical resection is the only curative treatment  
modality for cardiac myxoma. The standard approach is 
via median stermotomy under hypo-thermia and 
cardioplegic cardiac arrest with cardiopulmonary 
bypass. 
The tumour should be removed under direct 
visualisation and it is vital that fragments are not 
dislodged during surgery. The surgeon must also ensur  
that the other atria and ventricles are checked for 
fragments or other tumour foci. 
Complete resection involves the removal of the root of 
the pedicle attaching the tumour to the heart wall, and 
consequently a full-thickness removal of the attached 
inter-atrial septum where appropriate. This in turn 
creates an atrial septal defect that can be closed 
primarily with a pericardial or Dacron patch. 
In cases where the tumour is associated with the valve 
structures, it may be necessary to perform a 
concomitant valve repair, with or without annulo-
plasty, or, where this is impossible, a valve replace-
ment using an artificial prosthesis. 
Evolution 
Cardiac myxomas rarely metasasize, although should 
they do so, their common sites are the brain, sternum, 
vertebrae, pelvis and scapula. Without treatment, 
symptomatic patients showing dyspnoea and 
haemoptysis will likely die within 1-2 years or embolic 
complications or sudden cardiac death induced by 
complete valve-orifice occlusion by the tumour. 
Prognosis 
Long-term outcomes following complete resection of a 
cardiac myxoma are excellent, with a post-operative 
mortality rate of 0-3%. Due to their location within the 
heart, removal of the tumours may result in supra-
ventricular arrhythmias or atrio-ventricular node 
dysfunction requiring treatment. 
Cardiac myxomas only recur in 1-3% of cases, and in 




Chromosomal clonal structural aberrations appear to be 
the mechanism underlying cardiac myxoma formation, 
with defects at several foci denoted on chromosomes 2, 
12, and 17. Other defects include rearrangements 
focussed on chromosome 1q32, loss of the Y 
chromosome and chromosome 13 and 15 telomeric 
association. 
Cytogenetic analysis of myxomas in patients suffering 
from Carney Complex have shown a role for regions 
2p16 and 17q2, however cytogenetic analysis in cases 
of sporadic myxoma have shown no role for 2p16 and 
only a limited involvement in structural rearrangement 
for 17q2. Structural rearrangements in regions 17p1 
and 12p1 did occur more frequently, however, and so it
has been hypothesized that these regions may contain 
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genes important in the development of sporadic cardiac 
myxomas. 
Genes involved and proteins 
Note 
Studies have demonstratred that mutations in the 
PRKAR1a gene encoding the R1a regulatory subunit of 
cAMP-dependent protein kinase A cause autosomal 
dominant Carney Complex. This has led to the 
examination microdissected material from patients wi h 
sporadic cardiac myxomas for markers PRKAR1 9CA, 
D2S2153, D2S2251 and D2S123, however, no loss of 
heterozygosity was demonstrated, nor were any definite 
band changes suggestive of microsatellite instabiliy 
present. This has in turn led to the conclusion that 
sporadic cardiac myxomas are not genetically related to 
those found in Carney Complex, and that other, as yet 
unknown genetic mechanisms must be at work. 
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